Loading...
•
Dec 31, 2020
Equillium Q4 2020 Earnings Report
Equillium reported financial results for the fourth quarter and full year 2020 and provided a clinical development update.
Key Takeaways
Equillium reported a net loss of $8.9 million for Q4 2020, or $(0.36) per share. Research and development expenses were $6.6 million, and general and administrative expenses were $2.4 million. The company's cash, cash equivalents, and short-term investments totaled $82.2 million as of December 31, 2020.
Cash runway extended into the second half of 2023.
Positive interim data from EQUATE study in aGVHD was announced.
Multiple data and regulatory catalysts are expected in 2021.
A total of $83.7 million was raised in financing net proceeds in 2020 and through February 2021.
Equillium
Equillium
Forward Guidance
Equillium anticipates several catalysts in the near future.
Positive Outlook
- EQUALISE Phase 1b study: topline data from Type A patients (SLE), 1Q 2021
- EQUATE Phase 1b study: topline data in first-line aGVHD, 1H 2021
- Regulatory feedback on proposed pivotal study in first-line aGVHD, Mid-2021
- Initiate pivotal study in first-line aGVHD, 2H 2021*
- EQUALISE Phase 1b study: interim data from Type B patients (lupus nephritis), 2H 2021